Last quarter (Q4 2023), Iovance Biotherapeutics's total revenue was $482.00K, an increase of Infinity% from the same quarter last year. In Q4, Iovance Biotherapeutics's net income was $-116.36M. See Iovance Biotherapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	$ 1.19M	$ 1.19M	-	-	$ 0.00	$ 0.00
Cost of Revenue	$ 10.76M	$ 10.76M	-	-	-	-
Gross Profit	$ -7.52M	$ -9.57M	-	-	-	-
Operating Expense	$ 448.94M	$ 450.99M	$ 398.88M	$ -342.70M	$ 261.94M	$ 206.87M
Operating Income	$ -458.51M	$ -460.56M	$ -398.88M	$ -342.70M	$ -261.94M	$ -206.87M
Net Non Operating Interest Income Expense	$ 10.99M	$ 13.04M	$ 2.98M	$ 451.00K	$ 2.36M	$ 9.32M
Other Income Expense	-	-	-	-	-	-
Pretax Income	$ -447.52M	$ -447.52M	$ -395.89M	$ -342.25M	$ -259.58M	$ -197.56M
Tax Provision	$ -3.50M	$ -3.50M	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -444.06M	$ -444.04M	$ -395.89M	$ -342.25M	$ -259.58M	$ -197.56M
Basic EPS	$ -1.43	-	$ -2.49	$ -2.23	$ -1.88	$ -1.59
Diluted EPS	$ -1.43	-	$ -2.49	$ -2.23	$ -1.88	$ -1.59
Basic Average Shares	$ 683.99M	-	$ 159.26K	$ 153.41K	$ 138.30M	$ 124.34M
Diluted Average Shares	$ 683.99M	-	$ 159.26K	$ 153.41K	$ 138.30M	$ 124.34M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 233.37M	$ 461.75M	$ 398.88M	$ -342.70M	$ 261.94M	$ 206.87M
Net Income From Continuing And Discontinued Operation	$ -444.04M	$ -444.04M	$ -395.90M	$ -342.25M	$ -259.58M	$ -197.56M
Normalized Income	$ -223.71M	-	$ -312.76M	-	$ -259.58M	$ -197.56M
Interest Expense	-	-	-	-	-	-
EBIT	$ -327.33M	$ -447.52M	$ -395.89M	$ -342.25M	$ -261.94M	$ -206.87M
EBITDA	$ -199.68M	$ -417.96M	$ -374.28M	$ -322.26M	$ -253.22M	$ -205.70M

Currency in USD

Iovance Biotherapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing